DK3323814T3 - (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere - Google Patents

(2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere Download PDF

Info

Publication number
DK3323814T3
DK3323814T3 DK17195612.1T DK17195612T DK3323814T3 DK 3323814 T3 DK3323814 T3 DK 3323814T3 DK 17195612 T DK17195612 T DK 17195612T DK 3323814 T3 DK3323814 T3 DK 3323814T3
Authority
DK
Denmark
Prior art keywords
dipeptidylpeptidase
oxazepan
carboxamides
phenylethyl
cyano
Prior art date
Application number
DK17195612.1T
Other languages
English (en)
Inventor
Hans Roland LÖNN
Stephen Connolly
Steven Swallow
Staffan Po Karlsson
Carl-Johan Aurell
John Fritiof Pontén
Kevin James Doyle
Graham Peter Jones
David Wyn Watson
Jaqueline Anne Macritchie
Nicholas John Palmer
De Poël Amanda Jane Van
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3323814(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3323814T3 publication Critical patent/DK3323814T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
DK17195612.1T 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere DK3323814T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24
EP15701577.7A EP3097086B1 (en) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Publications (1)

Publication Number Publication Date
DK3323814T3 true DK3323814T3 (da) 2020-08-03

Family

ID=52432834

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17195612.1T DK3323814T3 (da) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere
DK15701577.7T DK3097086T3 (da) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyan-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidyl-peptidase i-hæmmere

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15701577.7T DK3097086T3 (da) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyan-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidyl-peptidase i-hæmmere

Country Status (37)

Country Link
US (16) US9522894B2 (da)
EP (3) EP3097086B1 (da)
JP (5) JP6469711B2 (da)
KR (1) KR102417684B1 (da)
CN (2) CN110483492B (da)
AP (1) AP2016009322A0 (da)
AR (1) AR099177A1 (da)
AU (4) AU2015208932C1 (da)
BR (1) BR112016016224B1 (da)
CA (1) CA2935625C (da)
CL (1) CL2016001889A1 (da)
CR (1) CR20160327A (da)
CY (2) CY1120049T1 (da)
DK (2) DK3323814T3 (da)
DO (1) DOP2016000175A (da)
EA (1) EA032794B1 (da)
ES (2) ES2808060T3 (da)
HK (2) HK1225730B (da)
HR (2) HRP20180116T1 (da)
HU (2) HUE038274T2 (da)
IL (3) IL246614B (da)
LT (2) LT3323814T (da)
MX (1) MX368840B (da)
MY (1) MY194850A (da)
NO (1) NO2699580T3 (da)
NZ (2) NZ722063A (da)
PE (1) PE20161218A1 (da)
PH (1) PH12016501439B1 (da)
PL (2) PL3097086T3 (da)
PT (2) PT3323814T (da)
RS (2) RS56919B1 (da)
SG (2) SG11201606052TA (da)
SI (2) SI3097086T1 (da)
TW (1) TWI690517B (da)
UY (1) UY35963A (da)
WO (1) WO2015110826A1 (da)
ZA (2) ZA201605856B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (da) 2014-01-24 2018-02-24
US20180028541A1 (en) * 2016-07-29 2018-02-01 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis
AU2019217870A1 (en) * 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
EP3758708A1 (en) * 2018-03-01 2021-01-06 AstraZeneca AB Pharmaceutical compositions comprising (2s)--{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
WO2020018551A1 (en) * 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)- n-[(1s)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
AU2019306532A1 (en) * 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
KR20210048431A (ko) * 2019-10-23 2021-05-03 주식회사 종근당 만성폐쇄성폐질환(copd)의 예방 또는 치료용 조성물
CA3181285A1 (en) * 2020-07-20 2022-01-27 Jessica BASSO Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
CN115996923A (zh) 2020-08-26 2023-04-21 四川海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
KR20230117738A (ko) 2020-12-04 2023-08-09 레이스톤 바이오파마 컴퍼니 리미티드 카텝신 c의 소분자 억제제 및 이의 의약적 용도
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
AU2022218443A1 (en) * 2021-02-05 2023-09-21 Medshine Discovery Inc. Fused ring derivatives containing 1,4-oxazepane
AU2022376535A1 (en) * 2021-10-29 2024-05-02 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
WO2023134656A1 (zh) * 2022-01-11 2023-07-20 上海壹典医药科技开发有限公司 一种肽基腈类化合物及其应用
WO2023159120A1 (en) * 2022-02-16 2023-08-24 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
WO2023160542A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 二肽基肽酶抑制剂化合物的盐及晶型
TW202333739A (zh) * 2022-02-22 2023-09-01 大陸商四川海思科製藥有限公司 二肽基肽酶1抑制劑多晶型物及其製備方法和用途
WO2023160541A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 一种含氮杂环化合物的制备方法
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
WO2023236879A1 (zh) * 2022-06-07 2023-12-14 瑞石生物医药有限公司 苯并[c]色满化合物的多晶型及其制备方法和用途
WO2023236877A1 (zh) * 2022-06-07 2023-12-14 瑞石生物医药有限公司 苯并[c]色满化合物的可药用盐、其多晶型及用途
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024081889A1 (en) 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
DK1317555T3 (da) 2000-09-08 2008-03-25 Prozymex As Dipeptidylpeptidase i krystalstruktur og anvendelser heraf
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
CN1315806C (zh) 2001-12-04 2007-05-16 霍夫曼·拉罗奇有限公司 取代的2－氨基－环烷烃甲酰胺和它们作为半胱氨酸蛋白酶抑制剂的用途
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
EP1975153A3 (en) 2003-05-30 2010-03-31 Prozymex A/S Protease inhibitors
EP1638925A1 (en) 2003-06-18 2006-03-29 Prozymex A/S Protease inhibitors
KR101504729B1 (ko) 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물
US20070286854A1 (en) 2004-04-28 2007-12-13 Bayer Healthcare Ag Diagnostics And Therapeutics For Diseases Associated With Dipeptidyl-Peptidase 1 (Dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
EA200971133A1 (ru) 2004-06-29 2010-10-29 Никомед Данмарк Апс Производство фармацевтических композиций с быстрым высвобождением на основе водонерастворимых лекарственных средств и фармацевтические композиции, получаемые способом по изобретению
US20090054358A1 (en) 2004-07-19 2009-02-26 The John Hopkins University Flt3 inhibitors for immune suppression
CA3054535A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MX2007015679A (es) 2005-06-30 2008-02-21 Amgen Inc Inhibidores de quinasa bis-aril y su uso en el tratamiento de inflamacion, angiogenesis y cancer.
EP2125816A2 (en) 2007-03-07 2009-12-02 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
BRPI0817311A2 (pt) 2007-09-25 2015-03-17 Novartis Ag Tratamento de doenças pulmonares com medicamentos em aerossol tais como a vancomicina
EA201000958A1 (ru) * 2007-12-12 2010-12-30 Астразенека Аб Пептидилнитрилы и их применение в качестве ингибиторов дипептидилпептидазы i
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
RU2016116516A (ru) 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
BRPI1016132B8 (pt) 2009-04-01 2021-05-25 Bial Portela & Ca Sa composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável
AU2010244218B2 (en) 2009-05-07 2012-07-19 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
CN103491777B (zh) 2011-02-11 2015-05-06 葛兰素史密斯克莱知识产权发展有限公司 组织蛋白酶c抑制剂
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
ES2674451T3 (es) 2012-02-21 2018-06-29 Merck Patent Gmbh 2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
JP6172143B2 (ja) 2012-04-17 2017-08-02 アステラス製薬株式会社 含窒素二環式芳香族へテロ環化合物
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
WO2014140091A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
NZ710034A (en) 2013-03-14 2020-06-26 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
EP2970228B1 (en) 2013-03-14 2017-05-10 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
EP2970230B1 (en) 2013-03-14 2019-05-22 Boehringer Ingelheim International GmbH Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
WO2015032945A1 (en) 2013-09-09 2015-03-12 Prozymex A/S Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
NO2699580T3 (da) 2014-01-24 2018-02-24
DK3466432T3 (da) 2014-05-15 2020-09-28 Insmed Inc Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
US9625460B2 (en) 2014-05-30 2017-04-18 Versitech Limited Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
KR102510588B1 (ko) 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 스피로사이클릭 억제제
CA2965566A1 (en) 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists
AU2016227618B2 (en) 2015-03-05 2020-06-04 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
US20180028541A1 (en) 2016-07-29 2018-02-01 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis
AU2019217870A1 (en) 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
EP3758708A1 (en) 2018-03-01 2021-01-06 AstraZeneca AB Pharmaceutical compositions comprising (2s)--{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
WO2020018551A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)- n-[(1s)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
EP4329767A1 (en) 2021-04-29 2024-03-06 Insmed Incorporated Certain-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis

Also Published As

Publication number Publication date
US11814359B2 (en) 2023-11-14
PL3097086T3 (pl) 2018-04-30
RS60639B1 (sr) 2020-09-30
CN105980367A (zh) 2016-09-28
NZ722063A (en) 2017-09-29
RS56919B1 (sr) 2018-05-31
PH12016501439A1 (en) 2017-02-06
AU2017200338B2 (en) 2018-03-01
US11655224B2 (en) 2023-05-23
US11655222B2 (en) 2023-05-23
US11673872B2 (en) 2023-06-13
JP2019070029A (ja) 2019-05-09
UY35963A (es) 2015-07-31
EA201691375A1 (ru) 2017-01-30
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
SG11201606052TA (en) 2016-08-30
CY1120049T1 (el) 2018-12-12
SG10201701056QA (en) 2017-03-30
ZA201800431B (en) 2019-09-25
JP6804570B2 (ja) 2020-12-23
JP6469711B2 (ja) 2019-02-13
SI3097086T1 (en) 2018-04-30
ZA201605856B (en) 2020-02-26
JP2023156479A (ja) 2023-10-24
HUE052421T2 (hu) 2021-04-28
EP3097086B1 (en) 2017-12-13
NZ734768A (en) 2022-09-30
EP3097086A1 (en) 2016-11-30
AR099177A1 (es) 2016-07-06
US20230278969A1 (en) 2023-09-07
EP3323814B1 (en) 2020-05-13
US20230115170A1 (en) 2023-04-13
DK3097086T3 (da) 2018-02-05
NO2699580T3 (da) 2018-02-24
SI3323814T1 (sl) 2020-10-30
HK1255870A1 (zh) 2019-08-30
US11680049B2 (en) 2023-06-20
US11673871B2 (en) 2023-06-13
US10287258B2 (en) 2019-05-14
DOP2016000175A (es) 2016-08-15
US11655221B2 (en) 2023-05-23
AU2015208932B2 (en) 2017-02-16
IL246614B (en) 2018-02-28
AU2015208932A1 (en) 2016-07-28
ES2658516T3 (es) 2018-03-12
PE20161218A1 (es) 2016-11-27
PH12016501439B1 (en) 2017-02-06
HRP20180116T1 (hr) 2018-03-23
US20230116721A1 (en) 2023-04-13
HK1225730B (zh) 2017-09-15
US20230028726A1 (en) 2023-01-26
ES2808060T3 (es) 2021-02-25
WO2015110826A1 (en) 2015-07-30
US20200017455A1 (en) 2020-01-16
JP2017503832A (ja) 2017-02-02
LT3097086T (lt) 2018-02-26
US20230250071A1 (en) 2023-08-10
MX368840B (es) 2019-10-18
CN110483492A (zh) 2019-11-22
IL252836A0 (en) 2017-08-31
MX2016009349A (es) 2016-10-13
CN105980367B (zh) 2019-08-23
TW201612167A (en) 2016-04-01
KR20160111470A (ko) 2016-09-26
AU2015208932A8 (en) 2017-03-09
JP7157791B2 (ja) 2022-10-20
JP2022096662A (ja) 2022-06-29
US20200247765A1 (en) 2020-08-06
JP7336563B2 (ja) 2023-08-31
US20170057938A1 (en) 2017-03-02
CY1123391T1 (el) 2021-12-31
US11117874B2 (en) 2021-09-14
EA032794B1 (ru) 2019-07-31
AU2018202956B2 (en) 2019-05-09
AU2015208932C1 (en) 2017-05-25
US20150210655A1 (en) 2015-07-30
JP2021046423A (ja) 2021-03-25
AU2018202956A1 (en) 2018-05-17
AU2017200338A1 (en) 2017-02-02
EP3744714A1 (en) 2020-12-02
AU2019202675A1 (en) 2019-05-16
US20230069044A1 (en) 2023-03-02
BR112016016224B1 (pt) 2023-02-23
US20230062646A1 (en) 2023-03-02
CA2935625A1 (en) 2015-07-30
CN110483492B (zh) 2023-07-21
AP2016009322A0 (en) 2016-07-31
US10669245B2 (en) 2020-06-02
HUE038274T2 (hu) 2018-10-29
AU2019202675B2 (en) 2020-05-28
LT3323814T (lt) 2020-10-26
CL2016001889A1 (es) 2016-12-09
PL3323814T3 (pl) 2020-10-19
US20180251436A1 (en) 2018-09-06
US9815805B2 (en) 2017-11-14
TWI690517B (zh) 2020-04-11
US20210238152A1 (en) 2021-08-05
US20230085620A1 (en) 2023-03-23
BR112016016224A2 (da) 2017-08-08
KR102417684B1 (ko) 2022-07-05
IL265611A (en) 2019-05-30
EP3323814A1 (en) 2018-05-23
US20230025351A1 (en) 2023-01-26
US11667615B2 (en) 2023-06-06
CR20160327A (es) 2016-10-20
CA2935625C (en) 2022-10-18
US11655223B2 (en) 2023-05-23
HRP20201147T1 (hr) 2020-12-11
MY194850A (en) 2022-12-19
US20230033573A1 (en) 2023-02-02
AU2015208932B8 (en) 2017-03-09
US9522894B2 (en) 2016-12-20
PT3323814T (pt) 2020-08-05

Similar Documents

Publication Publication Date Title
DK3323814T3 (da) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere
DK3461821T3 (da) Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
BR112017004334A2 (pt) inibidores de desmetilase específica de lisina-1.
BR112017012364A2 (pt) pré-tratamento rápido.
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
DK3256462T3 (da) Substituerede 2-thioimidazolyl-carboxamider som skadedyrsbekæmpelsesmiddel
ES1140983Y (es) Maquina de embalaje de termoconformado
DK3352817T3 (da) Injektionsapparat, navnlig som auto-injektor
DK3123576T3 (da) Modul, spesielt et industrielt modul
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
DK3233839T3 (da) Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer
ITRM20150057U1 (it) Imballaggio per articoli.
UA29878S (uk) Упаковка для зубочисток
TH1601002634B (th) เครื่องติดฉลาก
ITRM20140098U1 (it) Macchina utensile.
UA29501S (uk) Упаковка
UA28920S (uk) Пакет
UA28525S (uk) Упаковка
TH1501005075A (th) สารผสมการบ่ม-ความชื้นประเภทหนึ่งห่อ
TH1601001175A (th) บรรจุภัณฑ์
BR302014000338S1 (pt) Configuração aplicada em garrafa.
BR302014000025S1 (pt) Configuração aplicada em frasco.